Article (Scientific journals)
Real-world use of granulocyte colony-stimulating factor in ambulatory breast cancer patients: a cross-sectional study
Van Ryckeghem, F.; Haverbeke, C.; Wynendaele, W. et al.
2019In Supportive Care in Cancer, 27, p. 1099-1108
Peer Reviewed verified by ORBi
 

Files


Full Text
Real-world use of granulocyte colony-stimulating ... article GJ.pdf
Publisher postprint (609.48 kB)
Request a copy

All documents in ORBi are protected by a user license.

Send to



Details



Keywords :
Breast cancer; Chemotherapy; Febrile neutropenia; Granulocyte colony-stimulating factor; Prophylaxis
Abstract :
[en] Purpose: To prevent febrile neutropenia (FN), European Organisation for Research and Treatment of Cancer (EORTC) guidelines recommend primary prophylaxis with granulocyte colony-stimulating factors (PPG) for patients at high risk (≥ 20%) of FN. In Belgium, the use of PPG is restricted by specific reimbursement criteria. The impact of these criteria on PPG use and adherence to guidelines is unknown. Methods: This multicentre, cross-sectional, observational study aimed to describe PPG use by FN risk category in breast cancer patients who were scheduled to receive myelosuppressive chemotherapy in outpatient clinics in Belgium during a 2-week period between 13 October and 12 December 2014. Results: In total, 490 patients were enrolled. Median age was 57.0 years. Based on their chemotherapy regimen, 53.9, 5.1 and 41.0% of patients were at a low, intermediate and high risk of FN, respectively. Overall, 39.8% of patients received PPG (17.0, 12.0 and 73.1% of those receiving low-, intermediate- and high-risk regimens, respectively). In the high-risk category, PPG was used in 89.9% of dose-dense and in 25.0% of classical chemotherapy regimens. PPG use was adherent to EORTC guidelines in 75.3% of patients (30.6% appropriate use, 44.7% appropriate non-use). EORTC guidelines would recommend PPG use in 46.1% of this study population (n = 226), and its use was reimbursable in Belgium in 76.1% of these patients (n = 172), but only 66.4% of them received PPG (n = 150). Conclusions: Both Belgian reimbursement criteria and physician decision-making led to a proportion of patients for whom PPG treatment was recommended but finally not receiving it. © 2018, Springer-Verlag GmbH Germany, part of Springer Nature.
Disciplines :
Oncology
Author, co-author :
Van Ryckeghem, F.;  AZ Glorieux, Ronse, Belgium and Gent University Hospital, Ghent, Belgium
Haverbeke, C.;  Gent University Hospital, De Pintelaan 185, Ghent, Belgium
Wynendaele, W.;  Department of Medical Oncology, Imelda Hospital, Bonheiden, Belgium
JERUSALEM, Guy  ;  Centre Hospitalier Universitaire de Liège - CHU > Département de médecine interne > Service d'oncologie médicale
Somers, L.;  OncoLogX, Antwerp, Belgium
Van den broeck, A.;  Amgen, Brussels, Belgium
Vingerhoedt, S.;  Amgen, Brussels, Belgium
Van Belle, S.;  Gent University Hospital, De Pintelaan 185, Ghent, Belgium
Language :
English
Title :
Real-world use of granulocyte colony-stimulating factor in ambulatory breast cancer patients: a cross-sectional study
Publication date :
2019
Journal title :
Supportive Care in Cancer
ISSN :
0941-4355
eISSN :
1433-7339
Publisher :
Springer Verlag
Volume :
27
Pages :
1099-1108
Peer reviewed :
Peer Reviewed verified by ORBi
Available on ORBi :
since 29 May 2019

Statistics


Number of views
54 (8 by ULiège)
Number of downloads
0 (0 by ULiège)

Scopus citations®
 
5
Scopus citations®
without self-citations
5
OpenCitations
 
5

Bibliography


Similar publications



Contact ORBi